Production (Stage)
Relmada Therapeutics, Inc.
RLMD
$0.7085
-$0.0415-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -35.27% | -33.13% | -3.10% | -34.09% | -21.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.75% | -28.90% | 1.39% | -27.69% | -18.35% |
| Operating Income | 20.75% | 28.90% | -1.39% | 27.69% | 18.35% |
| Income Before Tax | 19.56% | 25.86% | 1.25% | 29.78% | 17.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.56% | 25.86% | 1.25% | 29.78% | 17.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.56% | 25.86% | 1.25% | 29.78% | 17.07% |
| EBIT | 20.75% | 28.90% | -1.39% | 27.69% | 18.35% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 20.29% | 26.05% | 1.50% | 29.95% | 17.16% |
| Normalized Basic EPS | 19.67% | 28.14% | -3.38% | 27.79% | 18.70% |
| EPS Diluted | 20.29% | 26.05% | 1.50% | 29.82% | 17.16% |
| Normalized Diluted EPS | 19.67% | 28.14% | -3.38% | 27.79% | 18.70% |
| Average Basic Shares Outstanding | 0.92% | 0.25% | 0.25% | 0.25% | 0.11% |
| Average Diluted Shares Outstanding | 0.92% | 0.25% | 0.25% | 0.25% | 0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |